24th September 2014

New NICE guidance means that the 1 million people taking warfarin in the UK can benefit from SelfieChek

Roche Diagnostics, Burgess Hill, 24 September 2014: The NHS regulator NICE has today recommended that people taking warfarin can monitor their own blood levels at a time and place convenient to them. In the guidance, NICE recommends using the CoaguChek® XS self-monitoring device.

This means that more people taking warfarin should be able to self-monitor (or ‘SelfieChek’), rather than being tied to frequent (sometimes weekly) clinic or hospital visits to have their blood clotting levels measured. Self-monitoring allows people taking warfarin to enjoy a flexible lifestyle and reduces the risk of stroke for people with atrial fibrillation or a replacement heart valve.i The guidance is also set to benefit the NHS by reducing the unnecessary burden that regular blood checks place on healthcare professionals’ time and resources.ii

Despite the recognised benefits, only 15% of GPs in the UK currently offer self-monitoring to their patients, with only 11% reporting that their practice has a policy of providing self-monitoring.iii In addition, of the 211 Clinical Commissioning Groups (CCGs) in England ─ the groups which decide the healthcare services that are available to people in their local area ─ only a third currently allow people to self-monitor.iv

Warfarin – which saw its 60th anniversary this year – is a tried and tested treatment used by nearly 1 million people in the UK. To coincide with the publication of the NICE guidance, Roche Diagnostics is launching the SelfieChek campaign to empower people taking warfarin and ensure that everyone who could benefit from self-monitoring is given the option to do so by their healthcare professional. The campaign highlights how easy it is to self-monitor and asks people who self-monitor to join the SelfieChek community and share their selfie photos on the SelfieChek Facebook page: www.Facebook.com/SelfieChek

Eve Knight, Chief Executive and Co-founder of the charity AntiCoagulation Europe said: “It’s a shame that so few GPs are currently making self-monitoring available to their patients, which means that people taking warfarin continue to struggle to fit in their regular appointments to have their blood checked with their work and family commitments. We hope today’s NICE guidance will mean that more GPs recognise the many health and lifestyle benefits of self-monitoring and allow their patients to benefit from the freedom and flexibility that SelfieChek brings.”
Dr Matthew Fay, a GP in West Yorkshire and member of the NICE Atrial Fibrillation Guideline Development Group, said: “The NICE guidance recognises that self-monitoring is accurate and reliable and that warfarin patients prefer the flexibility and reassurance it provides. With the NICE Clinical Guideline on Atrial Fibrillation (AF) published in June recommending that aspirin is no longer used for stroke risk reduction in people with AF, a further 300,000 people will need anticoagulation. Self-monitoring will reduce this increased burden on hospital and clinic resources. Patients taking warfarin should be supported to SelfieChek if it’s right for them and can find out more by speaking to their doctor.”

More information about self-monitoring and the CoaguChek XS device is available by calling the Freephone Careline: 0808 100 7666 and visiting the website: www.CoaguChek.co.uk

Notes to Editors

About the NICE guidance
The NICE diagnostics guidance Self-monitoring coagulation status in people on long-term vitamin K antagonist therapy who have atrial fibrillation or heart valve disease: point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor) is available at: http://guidance.nice.org.uk/DT/16

About the SelfieChek campaign
The Roche Diagnostics’ SelfieChek campaign aims to empower people taking warfarin to enjoy a flexible lifestyle by highlighting how easy it is for them to self-monitor. The campaign asks people who self-monitor to join the SelfieChek community and share their selfie photos on the SelfieChek Facebook page: www.Facebook.com/SelfieChek

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.


i Heneghan C, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. February 2006

ii Craig JA, et al. Warfarin monitoring economic evaluation of point of care self-monitoring compared to clinic settings. January 2014  

iii Roche data on file (GP Omnibus Survey). March 2014

iv ACSMA Freedom of Information requests to CCGs. May 2014